Heartseed Inc.
219A・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 8 directors (including 2 outside directors), and the Board of Corporate Auditors consists of 3 auditors (all outside auditors). The Board of Directors meets 16 times per year, with attendance by all members at nearly 100%. A Compensation Committee (with a majority of independent outside officers) has been established. No Nomination Committee has been established.
Risk Management
The company has established Compliance and Risk Management Regulations and holds a Compliance and Risk Management Committee, chaired by the President and Representative Director, semi-annually. Each department regularly identifies and assesses risks, and implements responses such as avoidance, reduction, transfer, and acceptance. An internal whistleblowing system (comprising an in-house contact point and a law firm) has also been established.
Shareholder Returns
Continuing a no-dividend policy. Annual dividends are forecast at ¥0 for both FY2025 (ending December 2025) and FY2026 (ending December 2026). Retained earnings carried forward remain negative, and the policy of prioritizing internal reserves for R&D for the time being remains unchanged.
Dividend Policy
The annual dividend for FY2025 (ending December 2025) was ¥0 (actual). The forecast annual dividend for FY2026 (ending December 2026) is also ¥0. Because retained earnings carried forward are negative and the company intends to actively pursue R&D for the time being, it does not plan to pay dividends for the foreseeable future. Internal reserves will be allocated to R&D. There have been no share buybacks (treasury shares outstanding at period-end were zero).
ESG
Promoting sustainability management under the vision of "Changing the world through regenerative medicine." Human capital is positioned as the top priority, with disclosed metrics including 100% paid leave utilization rate, 100% training participation rate, 100% health checkup attendance rate, and 45% telework utilization rate (exceeding the 30% target). Against a target of 0 turnovers, the actual result was 1.
Last updated: March 26, 2026